Exploratory genome-wide association analysis of response to ketamine and a polygenic analysis of response to scopolamine in depression

Abstract excerpt

Growing evidence suggests that the glutamatergic modulator ketamine has rapid antidepressant effects in treatment-resistant depressed subjects. The anticholinergic agent scopolamine has also shown promise as a rapid-acting antidepressant. This study applied genome-wide markers to investigate the role of genetic variants in predicting acute antidepressant response to both agents. The ketamine-treated sample...

Topics

Share this publication in a Topic to start or enrich a Post.

• Share to Mental Health Research Topics
• Share to Treatment of Major Depression
• Share to Tryptophan and brain disorders